Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay

Published:2011-02-21 Issue:5 Volume:52 Page:896-904
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Goh Hyun-Gyung,Lin Min,Fukushima Takashi,Saglio Giuseppe,Kim Dongho,Choi Soo-Young,Kim Soo-Hyun,Lee Jeong,Lee Young-Seok,Oh Sang-Mi,Kim Dong-Wook

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.555569

Reference20 articles.

1. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [editorial; comment]

2. Chronic Myeloid Leukemia

3. BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria

4. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia

5. How complete is “complete” molecular response in imatinib-treated chronic myeloid leukemia?

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease Response Assessment Modalities in Chronic Myeloid Leukemia: Past, Present, and Future;Indian Journal of Medical and Paediatric Oncology;2023-11-27

2. Liquid biopsies and minimal residual disease in lymphoid malignancies;Frontiers in Oncology;2023-05-09

3. Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia;Cancers;2023-01-06

4. Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient;Therapeutic Advances in Hematology;2023-01

5. Measurable residual disease after CAR T-cell therapy;Seminars in Hematology;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3